INTRODUCTION
Increased uptake of drugs by AMs may result in suboptimal efficacy for drugs with extracellular targets and potential adverse effects including phospholipidosis that may compromise patients' safety. The latter is associated with lysosomal sequestration of lipophilic amine drugs in AMs which may contribute significantly to their total intracellular concentrations and consequently distribution in tissues rich in lysosomes such as lungs, liver and kidneys 1 . In addition to the induction of phospholipidosis, the role of this process in drug efficacy and potential involvement in drug resistance and drug-drug interactions has been highlighted [2] [3] [4] [5] [6] [7] . Although total intracellular drug concentrations can be measured and related to external media drug concentrations, determination of unbound cytosolic and lysosomal concentrations is experimentally challenging.
While there is an increased interest in understanding intracellular distribution of drugs, investigation of lysosomal sequestration in AMs has remained limited despite their anticipated important contribution to the overall lung drug disposition. Recently, lysosomal sequestration has been proposed to lead to the retention and prolonged duration of action of a number of inhaled beta-adrenergic bronchodilators in the lung 8 where lysosome rich AMs are likely to be the key contributors. Consequently, use of in silico mechanistic models accounting for system and drug properties may be useful in providing dynamic assessment of intracellular concentrations and several processes occurring in cells such as transporter-mediated uptake/efflux, passive diffusion, metabolism, intracellular binding and lysosomal sequestration.
While no mechanistic model has incorporated all of these processes for a particular system so far, a number of studies have successfully captured one or more processes in a specific cell type or tissue [9] [10] [11] [12] [13] [14] [15] . The earlier work of Trapp and colleagues 16 have demonstrated the prediction of subcellular (mitochondria and lysosomes) distribution of model acidic, basic and zwitterionic compounds in a generic cell model, based on passive permeation of neutral and ionized species in consideration of membrane potentials and intracellular pH gradients 16, 17 . However, these models have not been adapted for a specific cell type and have not captured the interactions of the ionized forms of basic drugs with the membrane acidic phospholipids (AP), highlighted as an important contributor to intracellular accumulation of basic drugs and their partitioning in membranes 13, 18 .
Although a number of studies have investigated uptake and lysosomal sequestration of drugs in rat primary AMs and cell lines such as NR8383 [19] [20] [21] [22] [23] [24] [25] , there has been no attempt to characterize this process in human AMs. One of the aims of this study was to investigate intracellular accumulation of a range drugs with respiratory indication and both extra-and intracellular targets in human AMs. Drugs included in the study were clarithromycin, formoterol, terbutaline, fenoterol, rifampicin, budesonide, ipratropium and tiotropium bromide, as analyzed previously by our group in NR8383 25 . Furthermore, lysosomal sequestration of clarithromycin and the prototypical lysosomotropic drug imipramine (positive control) 26 was investigated in human AMs freshly isolated from different patient donors to evaluate the inter-individual variability in this process. The in vitro data in human AMs were compared to those previously obtained in NR8383 cells 25 to assess the validity of this cell line as an in vitro tool for the prediction of drug accumulation in human AMs. In addition to the in vitro assessment, the generic in silico cell model reported by Trapp et al. (2008) 16 was modified by incorporating cell parameters specific for human AMs (e.g., lysosomal volume, pH of different organelles) and relevant drug physicochemical properties (logP, pKa); lipid partitioning and electrostatic interactions were also accounted for. The developed in silico AM model was subsequently assessed as a tool to predict drug accumulation in human AMs and particularly in lysosomes using the dataset of investigated respiratory drugs. Three subtypes of the in silico AM model were evaluated; the models only differed in their description of drug interaction with membrane phospholipids. Cellular accumulation (as assessed by cell-to-unbound medium concentration ratio, K p,cell ) and extent of lysosomal sequestration of drugs predicted by the in silico AM models were compared to the experimental data obtained in human AMs and the NR8383 cell line using indirect methods.
MATERIALS AND METHODS

Chemicals and Reagents
1-Aminobenzotriazole, ammonium chloride, ciprofoxacin, clarithromycin, dimethyl sulphoxide, imipramine, lactate dehydrogenase activity assay kit, Trypan blue 0.4% and verapamil hydrochloride were all from Sigma Aldrich Ltd., Dorset, UK. Budesonide, ipratropium bromide, fenoterol, formoterol, terbutaline and tiotropium bromide were all supplied by GlaxoSmithKline, UK. Chloroform and formaldehyde 37-41% were from Fisher Scientific, Loughborough, UK. 
Source and preparation of human alveolar macrophages
The human alveolar macrophages were obtained from patients undergoing lung surgery at the Ethics Committee and all subjects gave written informed consent to participate. Nine patients undergoing surgical resection for suspected or confirmed lung cancer were recruited for human alveolar macrophage assays. Patients were categorized as either smokers (≥1 pack year history) or non-smokers (<1 pack year history). All patients with the exception of one had normal lung function as predicted forced expiratory volume in 1 second FEV1, >80%, and FEV1/Forced vital capacity (FVC) ratio, >70% (Table S1 , Supporting Information). All patients were known to be free from any medications at the time of surgery except one patient who had salbutamol in medication history; details of medication prior to surgery were unknown.
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The isolation of the cells from the lung surgery sections was performed as described briefly herein: Areas of lung distant from the tumour were perfused with 0.1M sodium chloride. The resulting cell suspension was centrifuged (400g, for 10 minutes, at room temperature) and the cell pellet was re-suspended in RPMI-1640 medium. The cells were layered over a Ficoll-paque gradient. The mononuclear cells at the Ficoll interface were extracted, washed and re-suspended in the complete growth medium (CGM): RPMI-1640 medium containing 10% v/v FBS, 1% v/v 200 mM L-glutamine, 1% v/v 100 units/ml penicillin and 100 µg/ml streptomycin. Following isolation, the cells were maintained in this CGM in the fridge before the start of the experiments.
All experiments were initiated within 24 hours of surgery. The growth medium covering the macrophage cell monolayers was replaced with fresh medium before the start of the accumulation experiments in order to remove any remaining red blood cells. Further details on the AM isolation method and characterization of AM phenotype and activation state from resected lung tissue have been reported previously [27] [28] [29] .
In vitro accumulation and lysosomal sequestration of drugs in human AMs
In the current study, the accumulation of 9 drugs was assessed in human AMs using the method adapted from previous study in NR8383 cells 25 . Following the isolation and re-suspension of the cells in 1 mL CGM, the cell count and viability were assessed with Trypan-blue exclusion method using a haemocytometer under the light microscope (Leica Microsystems ATC2000, Milton Keynes, UK). The cells were then further supplemented with the CGM and 0.4 mL of the cell suspension was dispensed into collagen-I coated 24-well plates (BD Biosciences, Oxford, UK), seeding the wells at a density of 0.4 x 10 6 cells (0.3 x 10 6 in cases of insufficient number of cells). This seeding density was selected to accommodate the experimental set up that included several washing steps before accumulation studies and detachment of a substantial number of cells from the wells (~30% of the initial seeding density). After 2 hours of plating the cells at 37°C, 5% CO 2 incubator (CO 2 incubator, MCO-17AIC, Sanyo Biomedical, Loughborough, UK), the existing medium was replaced with the pre-warmed fresh medium to remove any unattached cells other than AMs which remained after their isolation. The plates were returned to the 37°C incubator and cultured for another 2 hours before the start of the uptake experiments. At this culture time, the cells were >70% confluent in wells and almost completely attached to the collagen support. The accumulation experiments at 37°C were performed on a single occasion for each drug investigated except for clarithromycin and imipramine (multiple donors). The investigation of lysosomal sequestration of basic drugs using ammonium chloride (NH 4 Cl) was performed as described previously 25 . Among the drug dataset, clarithromycin was selected for the assessment of lysosomal sequestration in human AMs, following positive findings in NR8383 cells. In addition, imipramine was included as a positive control, consistent with experiments in NR8383. All cell lysates and media samples were kept at -20°C overnight before analysis by LC-MS/MS. The amount of protein in each well was measured to determine the cell number using BCA protein assay.
Sample preparation and mass spectrometry analysis
Preparation and analysis of the cell lysate and media samples, and quantification of drug concentrations by LC-MS/MS were the same as in the previous study 7 . A calibration standard, containing the drug of investigation at a concentration range covering that of the experimental samples with an additional zero blank, was prepared in the same matrix of the experimental samples when sufficient number of human AMs was provided. When this was not the case, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 NR8383 cell lysates were used; a matrix made of NR8383 cells was considered to be the closest to human AMs due to the use of the same cell type.
Determination of drug accumulation
Accumulation of drugs in human AMs was determined by calculating K p,cell at 5 µM drug concentration at 10 minutes from the cell-to-unbound medium concentration ratio 30, 31 
Determination of lysosomal sequestration
Lysosomal sequestration of clarithromycin and imipramine in human AMs was determined using indirect method based on the assumption that NH 4 Cl abolishes pH gradient between cytosol and lysosomes. The advantages and limitations of indirect methods have been discussed previously 25 .
K p,cell in the presence and absence of NH 4 Cl was determined in at least same 4 donors of AMs for both drugs. The reduction in K p,cell of each drug in the presence of NH 4 Cl was expressed as a percentage relative to control and used as an indicator of the extent of lysosomal sequestration in human AMs. 
Statistical analysis
The arithmetic mean, standard error and coefficient of variation (CV) were calculated for K p,cell where the data were determined on more than one occasion. Geometric mean fold error (gmfe) was calculated (Eq. 1) in order to assess the discrepancy between NR8383 and human AM K p,cell data.
where N is the number of observations. When assessing lysosomal sequestration, the control and NH 4 Cl treated cells were compared using the two-tailed, paired t-test in order to determine the existence of a statistically significant difference between the two conditions. The data were considered to be statistically significant when p < 0.05.
Assessment of lysosomal sequestration in human AMs using Lysotracker ® Red (LTR)
Localization of lysosomes and assessment of lysosomal sequestration in human AMs were performed as previously 25 with a minor change in the seeding density of human AMs in collagen-I coated Ibidi 8-well chamber slides (200,000 cells/well). Following the procedure, the cells were examined for the detection of LTR with a confocal laser scanning microscope (Zeiss LSM 510, Jena, Germany). The details of this system, image processing and the quantification of LTR fluorescence intensity were as reported previously 7 .
Assessment of cytotoxicity of NH 4 Cl in human AMs
The incubation medium consisting of 5 µM clarithromycin and imipramine in the absence and presence of 20 mM NH 4 Cl were tested for cytotoxicity using the LDH assay kit (Sigma-Aldrich, Dorset, UK). Extensive assessment of cytotoxicity including the effect of NH 4 Cl alone on the 16 . Differences in drug ionization according to pH differences between medium, cytosol, lysosomes and mitochondria are likewise considered (pH partitioning), along with drug partitioning of neutral and ionized species into cell and organelle membranes. The model development was supported by collation of literature reported relevant cell parameters for AMs; details of parameters are listed in Table 1 . The distribution of a basic drug in AMs involving these processes is illustrated in Figure 1 . 
Flux of neutral and ionized drug species across membranes
The total diffusive flux of drugs across membranes was described as the sum of the flux of neutral (Fick's 1 st Law of Diffusion) and ionized (Nernst-Planck equation) species according to Eq. 2:
where P is permeability, C is concentration, N = zE m F/(RT); z is the electric charge of ionic species, E m is the membrane potential (V), F is the Faraday constant (96,484.56 C.mol -1 ), R is the universal gas constant (8.314 J.mol -1 .K -1 ) and T is the absolute temperature (310.16 K) 16 . The subscripts N and D represent neutral and dissociated (ionized) species, respectively.
Membrane permeability
The membrane permeability was predicted, assuming drug partitioning into membranes was adequately defined by partitioning into octanol. The permeability of neutral species (P N ) across membranes was described by Eq. 3. where DC is the diffusion coefficient (10 -14 m 2 s -1 for all drugs), K ow is the octanol-water partition coefficient of neutral species and dx is the membrane thickness.
Regarding the permeability of ionized species, a further 3.5 log unit reduction in lipophilicity was included as a penalty term for every charge a drug molecule possessed (e.g., 3.5 and 7 log unit for mono and diprotic drugs, respectively) 16 . 
Membrane partitioning
Three subtypes of in silico AM model were explored; the physiological structure and parameters of these models were the same with the exception of the description of membrane partitioning of drugs, as summarized in Table 2 . In the AM model (1), drug partitioning into membranes was based on the assumption that this process is adequately defined by drug partitioning into octanol 16 . Taking the lipid content of the cells into consideration, total drug partitioning into membrane lipids was described by Eq. 4.
where L is the fractional lipid content (vol/vol), K ow and K ow,D are the octanol-water partition coefficients of neutral and ionized species. The fractions of neutral (f N ) and ionized (f D ) species based on Henderson-Hasselbalch principles (Eq. S1-7, Supporting Information) and membrane partitioning were subsequently used in equations describing the fractions of neutral (Eq. 5) and ionized (Eq. S8, Supporting Information) species in cell model compartments.
where C N,f and C T are concentration of neutral species which can freely permeate membranes and the total concentration, respectively, W is the fractional water content (vol/vol). The Eq. 5
provides an example for a monoprotic drug, however can be extended to cover drugs with multiple charges e.g., i is indicates the existence of ionized species and n is the number of ionized species.
In contrast to AM model (1), AM model (2) takes into account interactions of cationic drug species with acidic phospholipids. Therefore, the term "LxK ow " in Eq. 4 was replaced with experimentally determined cell-to-unbound medium concentration ratio obtained in the presence of NH 4 Cl (K p+NH4Cl ) (Eq. S9, Supporting Information). The rationale for this approach was that in the presence of NH 4 Cl, lysosome-cytosol pH gradient is diminished and the remaining intracellular accumulation was assumed to reflect membrane partitioning (i.e., minimal active uptake). Alternatively, the minimum cell-to-unbound medium partition coefficient (K p,min ), representing drug partition into membranes when active processes are saturated at high substrate concentration 18 can be used for this purpose. This approach was not feasible here due to limited availability of human AMs. In the case of basic drugs in the dataset (pK a >8) ionized species will contribute predominantly to K p+NH4Cl due to their extensive ionization at physiological pH.
Therefore, it was assumed that K p+NH4Cl represents the distribution of ionized species between the membrane and aqueous compartments. To account for the distribution of neutral species (equivalent of LogP), K p+NH4Cl was extrapolated to K p+NH4Cl,n by assigning 1.0 log unit higher distribution for the latter. This difference between the distribution of neutral and ionized species was within the range of values (0-1.8) reported for basic drugs assessed in liposomes as closer membrane mimetic than octanol [35] [36] [37] [38] [39] [40] [41] [42] [43] . Once K p+NH4Cl,n was defined, a 1.0 log unit penalty in partitioning was applied for every charge of the drug molecule. The K p data were then used in equations describing the fractions of neutral (Eq. S9, Supporting Information) and ionized (Eq.
S8, Supporting Information) species in each cell model compartment.
In contrast to above, membrane partitioning was predicted in the AM model (3) by incorporating the cell specific AP concentration (mg/g cell) and the association constant of cationic drugs with AP (K a ) using the Rodgers & Rowland model 1 . Furthermore, the interaction of neutral drug with the fraction of neutral phospholipids (NP) and neutral lipids (NL) was considered. Consequently, the equations describing the fraction of neutral (Eq. S10) and ionized (Eq. S8) drugs in each compartment were revised ( Table 2) . Binding of cationic drugs to NL and NP was neglected.
Parameterization and assumptions of the in silico AM model
The in silico AM model was parameterized using both AM cell and drug specific parameters.
The AM cell parameters were collated from available literature; details are listed in Table 1 .
Most of the data were collated in human (non-smoker and smoker) and rat AMs with the exception of pH and E m of which the majority of the data was from primary macrophages or macrophage cell lines of other species, or other cell types including rat hepatocytes. Lysosomal (V lys ) and mitochondrial (V mit ) volumes in human AMs were calculated from the information that lysosomes contribute 9.3% on average (ranged 5.8-13.6%, CV<30%) to the total cell volume (V cell ), whereas contribution of mitochondria is 3.8% (ranged 3.0-4.9%, CV<30%) in rat AMs (Table S2 , Supporting Information), assuming the volume fractions were the same in both systems. The surface area of both cell and organelles were calculated from the volume of the respective compartments, assuming they were spheres. In general, the fractional lipid and water content of the cell and organelles were 0.05 and 0.95 vol/vol, respectively 16, 17 . In the AM model (3) where the volume fractions of AP (0.0123), NP (0.0549) and NL (0.0188) were considered 44, 45 , the lipid and water contents were 0.0860 (sum of lipid fractions) and 0.914 (1-sum of lipid fractions), respectively. The AP concentration of AMs was 12.34 mg/g of cell 44, 45 and the AP composition of lysosomal, mitochondrial and plasma membrane was assumed to be the same.
The plasma and organelle membrane thickness of AMs was assigned as 9 nm, generic to plasma membranes 46 . The drug specific parameters were the octanol-water partition coefficient, LogP, acid-base dissociation constant(s), pK a (Table 3) , K a and K p+NH4Cl ( 25 for data in NR8383). As the K a data were not readily available, this parameter was calculated for red blood cells (K a,BC , Table S4 , Supporting Information) which also contain AP and assumed that it was representative of the K a in AMs, as done previously 1 . In cases where negative K a,BC values were obtained, the association of the drug with blood cells was assumed to be negligible and this parameter was set to zero. In vitro K p+NH4Cl was not available for all individual AM donors; in those cases the average % lysosomal contribution to the accumulation of clarithromycin and imipramine in human AMs was used to estimate K p+NH4Cl and for the prediction of K p,cell in AM model (2) ( Table S5 , Supporting Information). Subsequently, the inter-individual variation in predicted K p,cell of both drugs was assessed.
In silico cell model outputs
The in silico AM models were used to predict intracellular concentrations of the respiratory drugs, including also concentrations in lysosomes, mitochondria and cytosol. Drug concentrations in all AM model compartments were predicted at steady-state when net flux was zero. Differential equation describing changes in lysosomal drug concentration is illustrated in Eq. 6, whereas equations for remaining cellular compartments (e.g., cytosol, mitochondria) are shown in the Supporting Information (Eq. S11-14). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 where C, F, P, SA, V and N represent concentration, fraction, permeability, surface area, volume and number, respectively and the subscripts N, D, med, cell, c, l and m represent neutral, ionized, medium, total cell, cytosol, lysosomes and mitochondria, respectively. The total cell concentration was the sum of cytosolic, lysosomal and mitochondrial concentrations. The N/e N -1 ratio represents Nernst Plank equation 16 . The cell and organelle number was 1.
The numerical solution of the implemented equations was performed using ordinary differential 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
RESULTS
In vitro assessment of drug accumulation in human AMs
Accumulation of drugs previously investigated in NR8383 25 was assessed in freshly isolated human AMs and the data between the two in vitro systems were compared. Studies in human
AMs showed over 1500-fold range in K p,cell of investigated drugs, with the most extensive accumulation seen for imipramine (K p,cell = 853, CV 63%) ( Table 3 Table 3) . Comparison of the K p,cell data between human AMs (K p,hAM ) and NR8383
(K p,NR8383 ) showed a good agreement between the two systems, with an overall bias of 2.45-fold (gmfe). The ratio of K p,NR8383 and K p,hAM for 7 out of 9 drugs was within 3-fold error ( Figure 3 ).
K p,cell for clarithromycin, imipramine, terbutaline and budesonide showed a particular good agreement (within 2-fold), whereas the most pronounced outliers were fenoterol and tiotropium bromide. These two drugs had approximately 8.5-fold higher accumulation in NR8383 relative to human AMs. 
In vitro assessment of lysosomal sequestration in freshly isolated human AMs
Among drugs studied in human AMs, clarithromycin and imipramine were selected for investigation of lysosomal sequestration using indirect method. The concentration of NH 4 Cl and the incubation conditions used were the same as in NR8383 to allow direct comparison between the two systems. The pH of incubation medium containing NH 4 Cl was stable through the experimental set up, as a minor reduction (< 0.05 unit) in the pH was observed relative to control medium.
The effect of NH 4 Cl on clarithromycin K p,cell was investigated in a subset of human AM donors, as shown in Figure 4A . The reduction in clarithromycin K p,cell in human AMs ranged from 57%
to 67% between different donors (CV 7.7%). Overall, this reduction was not as pronounced as in the case of NR8383 (84%, Figure 4A was consistent between AM donors (CV=13%).
In the case of imipramine, K p,cell was reduced by 47 to 72% across 5 human AM donors investigated ( Figure 4B ). The mean K p,cell in human AMs under the control and NH 4 Cl treatment conditions were 963 (CV 54%) and 316 (CV 38%), respectively. On average, the total cellular accumulation of imipramine was reduced by 62% (CV 20%) in the presence of NH 4 Cl ( Supporting Information). The observed reduction in K p of imipramine was similar to that observed in NR8383 ( Figure 4B ). The K p,control /K p+NH4Cl ratio ranged between 1.9-3.5 among AM donors, suggesting a similar magnitude of saturable process. The extent of lysosomal sequestration was the lowest for both drugs in AMs from donor 9; however, the rank order across other overlapping donors differed between clarithromycin and imipramine.
Microscopic examination of human AMs showed presence of large number of lysosomes, as evident by the localization of LTR in these organelles (
Figure 5B Figure 4B ). The imaging results previously reported in NR8383 cells 25 were in good agreement with the current findings in human AM.
In silico prediction of drug accumulation in NR8383 cells
Using the drug and AM specific cellular parameters (Table S2 , Supporting Information), the accumulation of 10 drugs previously assessed in NR8383 in vitro was predicted using the developed in silico AM models. The comparison of the predicted K p,cell by all 3 models and the K p,cell obtained in NR8383 cells is shown in Figure 6 ; individual predicted K p,cell and K p for other cellular model compartments (lysosomes, mitochondria and cytosol) are listed in Table S6 , Supporting Information. In the case of the AM model (1), overall predictive bias was 7.8-fold (gmfe). The accumulation of basic terbutaline and formoterol and neutral budesonide was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 predicted within 3-fold of the observed data. In contrast, over-prediction of cellular accumulation was observed for basic fenoterol (3.8-fold) and permanently charged ipratropium and tiotropium bromide (>19-fold). In the case of basic clarithromycin and imipramine, the predicted K p,cell was <10% of the observed data. For zwitterions rifampicin and ciprofloxacin, the predicted K p,cell was <1% and ~14% of the observed K p,cell , respectively. Use of the in silico AM model (2) reversed this under-prediction trend, resulting in reduced bias (5.7-fold) and successful prediction of the intracellular accumulation for 40% of drugs, including clarithromycin and imipramine. However, for the remaining drugs in the dataset, the K p,cell was over-predicted by this model (between ~4-to 26-fold for terbutaline and tiotropium bromide, respectively). Using the AM model (3), the accumulation of imipramine, clarithromycin, budesonide and rifampicin was predicted within 3-fold of the observed data, whereas predicted K p,cell of ciprofloxacin was ~14% of the observed data. For the remaining drugs, a general trend of over-prediction of intracellular accumulation was evident, with most pronounced over-prediction of K p,cell observed for formoterol and fenoterol. The overall predictive bias of this model (8.4-fold) was larger than that observed for the other two models.
In silico prediction of lysosomal sequestration in NR8383 cells
In addition to the prediction of K p,cell , the ability of the in silico models to predict the extent of lysosomal sequestration of investigated drugs in NR8383 25 was evaluated. A 30% reduction in K p,cell cut-off and categorical prediction (TP, TN, FP and FN) with probability assessment (Table   S7 , Supporting Information) were used to evaluate the prediction success of each of the models.
Among the drugs studied, clarithromycin, imipramine and fenoterol were the three drugs for which lysosomal sequestration was correctly predicted as TP by both models (2) and ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 7). In contrast, model (1) significantly under-estimated the extent of lysosomal sequestration of imipramine (lysosomal K p of 38, <5% of the overall cellular accumulation). Using the 30% cutoff, the sensitivity of AM model (2) and (3) was 75%, whereas 50% was achieved by the model (1) ( Table S7 , Supporting Information). All the in silico models showed high ability to correctly assign non-lysosomotropic drugs, resulting in good specificity (>83% for model (2) and 67% for the other models). In the current dataset, terbutaline, rifampicin, budesonide, ipratropium and tiotropium bromide were predicted by all in silico models as non-lysosomotropic. The model predictions were inconsistent with reported 46% reduction in ipratropium bromide K p,cell 25 (FN);
however, the physicochemical properties of this drug and the variability in the in vitro data support its non-lysosomotropic classification. Models (2) and (3) had a comparable false negative rate of 25% relative to model (1) (50%).
The lysosomal sequestration of 80% of investigated drugs (TN and TP) was correctly predicted
only by the AM model (2). This model also had the lowest incidence of false positives (10%), resulting in the lowest PPE of 25% (Table S7 , Supporting Information). The most prominent FP was formoterol, as all 3 models predicted its substantial accumulation in lysosomes (>80%), as opposed to <30% observed in vitro. In the case of ciprofloxacin, only model (2) correctly predicted its non-lysosomal cellular accumulation.
In silico prediction of drug accumulation and lysosomal sequestration in human AMs
Imipramine and clarithromycin K p,cell and lysosomal K p were also predicted in human AMs (parameterized accordingly as in Table 1 ) due to availability of in vitro data in multiple donors for these two drugs. The intracellular accumulation of both drugs predicted by all 3 in silico AM models is shown in Figure 8 . Analogous to evaluation against NR8383 data, performance of the (2)), intracellular accumulation of both drugs was predicted within 3-fold of the observed data, with an overall bias of 1.83-fold.
Furthermore, the model (2) captured successfully the variation in the observed K p,cell of clarithromycin (CV 74%) and imipramine (CV 63%), as the predicted K p,cell ranged between 84-788 (CV 74%) and 390-1439 (CV 48%), respectively. In the case of the AM model (3), imipramine K p,cell was predicted within 3-fold, whereas clarithromycin predicted K p,cell was on the borderline 3-fold error.
In addition to the K p,cell prediction, all 3 models were evaluated for their ability to predict the extent of lysosomal sequestration of both drugs in human AMs (Table 4 ). The predicted contribution of lysosomes to clarithromycin accumulation in human AMs ranged between 56 and 74% by the AM model (1) and (3), respectively. This was in good agreement with the observed data for clarithromycin both in individual donors (ranged between 57-67 %) and the mean data (63 ± 4.8 %). In the case of imipramine, the model (1) significantly under-predicted the extent of its lysosomal sequestration; predicted contribution of lysosomes was 4.5% of the observed data.
In contrast, the model (2) and (3) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 of present findings to the in vivo situation requires also consideration of drug formulation, particle size, physiological and disease conditions.
The paucity of in vitro drug accumulation studies in human AMs does not permit extensive comparison of the data presented here with the literature (Table S8, 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Potential contamination with red blood cells in the experimental set up cannot be excluded, but all efforts were made to minimize this aspect.
The extent of lysosomal accumulation of both drugs in human AMs was comparable. However, it was evident that in all AM samples in which lysosomal sequestration of both drugs was assessed, the baseline accumulation of imipramine (in the presence of NH 4 Cl) was much higher compared with clarithromycin. The variability associated with clarithromycin K p+NH4Cl (62%) was larger relative to imipramine (38%). These results can be rationalized by differences in lipophilicity and amphiphilicity of these drugs and their interactions with membrane acidic phospholipids. Macrolides (including clarithromycin) have been shown to bind close to the surface of dodecylphosphocholine micelles as a membrane mimetic, where predominantly electrostatic interactions between the polar lipid head groups and positively charged amino groups of macrolides occur 58 . In the case of imipramine, partitioning into membranes is expected to be much greater, due to both electrostatic interactions with phosphate head groups and hydrophobic interactions with the fatty acid chains in the core of the membrane bilayer 59, 60 .
While the comparison of the K p,cell data from NR8383 with those from human AMs showed an overall good agreement between the two systems, the human AM data should be viewed as preliminary, highlighting the necessity for further studies. Nevertheless, the presented data 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 In silico assessment of intracellular drug accumulation and lysosomal sequestration in AMs
In the current study the in silico AM model was developed accounting for specific cell properties of alveolar macrophages (e.g., lysosomal contribution to the cellular volume). Three subtypes of the model were considered with respect to their description of membrane partitioning of drugs and these were evaluated for predicting K p,cell and the extent of lysosomal sequestration in AMs.
It was evident that the AM model (1) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 epithelial cells and OCT-transfected cells [61] [62] [63] [64] [65] . Therefore, if these transporters were present in AMs (sparse data so far in healthy and smoker subjects 57, 66 ), the K p+NH4Cl would also reflect the contribution of transporter-mediated active processes and may over-estimate the extent of membrane partitioning for drugs like terbutaline or formoterol.
In order to overcome the requirement for an experimentally determined data to describe drug membrane partitioning, AM model (3) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 estimation of the association constant for acidic phospholipids (K a,BC as surrogate) is appropriate for the basic as well as zwitterionic drugs with basic pK a ≥ 7 (ciprofloxacin) in the dataset 69 , whereas for zwitterions with basic pK a < 7 (rifampicin) and neutral drugs, it would be beneficial to consider also association with albumin and lipoprotein, respectively 69 . The goal of the current study was to develop a model which would predict primarily the extent of lysosomal sequestration of basic drugs; therefore, appropriate modifications in equations related to neutral, One of the key advantages of the in silico cell model developed in the current work is its ability to predict drug concentrations in the cytosol and lysosomes which are experimentally challenging to obtain. In addition, the in silico cell models presented here for AMs can be adapted to any cell type by modifying the system specific input parameters (volume, membrane electrical potential, pH). This is particularly important for identifying compounds with tendency to accumulate in lysosome-rich tissues such as lungs, liver and kidneys and to what extent this process may affect drug efficacy or potential adverse effects (e.g., phospholipidosis). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 development of the in silico model when appropriate supporting data become available. In silico cell models that are applicable to many different cell types and have the ability to account for both system and drug properties are valuable in facilitating compound selection in drug discovery and to guide experimental design. Likewise, the in vitro generated data are used to evaluate the performance of these models and inform further refinement.
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